Neuroscience
A press release from earlier today by Pfizer:
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program
[snip]
Read the full release
===
Alzheimer’s Association statement on negative Phase III trial results for latrepirdine (Dimebon)
03 March 2010
Read the statement
===
From ABC News:
Pfizer Alzheimer's Drug Dimebon Fails in Study
Late Stage Trials Show No Effect But Drug May Still Have a Future
By COURTNEY HUTCHISON
ABC News Medical Unit
March 03, 2010
Read the full article
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 14; Authors: Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans...
- Alzheimer Disease: Dimebon Results, Part Ii
From The New York Times: Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing...
- Neuropsychology Abstract Of The Day: Agitation In Alzheimer's Disease (ad)
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation...
- Abstract Of The Day: Alzheimer Disease Drug Treatments
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD005593. BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients...
- Modafinil For Fatigue In Multiple Sclerosis
B. Stankoff, MD, PhD, E. Waubant, MD, PhD, C. Confavreux, MD, G. Edan, MD, M. Debouverie, MD, L. Rumbach, MD, T. Moreau, MD, PhD, J. Pelletier, MD, PhD, C. Lubetzki, MD, PhD, M. Clanet, MD, PhD and French Modafinil Study Group. Modafinil for fatigue in...
Neuroscience
Alzheimer Disease: Dimebon Results
A press release from earlier today by Pfizer:
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program
[snip]
"About the CONNECTION Study[snip]
"CONNECTION is a Phase 3, multi-national, double-blind, placebo-controlled safety and efficacy trial involving 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. Patients had a mean age of 74.4 years and a mean score of 17.7 on the Mini-Mental State Examination (MMSE) upon entry into the study. More than 40 percent of the patients enrolled were in the United States. In the study, patients were randomized to one of three treatment groups, receiving dimebon 20 mg three times a day (TID), dimebon 5 mg TID, or placebo TID for six months. The 5 mg arm was included in the study to help define the effective dose range for dimebon treatment.
"No statistically significant improvements for the 20 mg TID group relative to placebo were achieved on the co-primary endpoints. One primary endpoint evaluated the effect of dimebon on cognition, as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), and showed that dimebon-treated patients achieved a 0.1 point difference from patients receiving placebo (p=0.86). Neither group was significantly changed from baseline. The other primary endpoint evaluated the effect of dimebon on independently-rated global function over the course of the six-month trial, as measured by the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus; p=0.81). According to the CIBIC-plus scale, 64.9 percent of the patients treated with dimebon 20 mg TID showed improvement or no change at Week 26 compared to 65.4 percent of placebo-treated patients. Results for the dimebon 5 mg dose were similar to the dimebon 20 mg and placebo, although they were numerically lower.
"The 20 mg TID dimebon-treated patients also showed no statistically significant differences compared to placebo on the secondary efficacy endpoints. After six months of treatment, patients treated with dimebon showed a 0.4 point difference from patients taking placebo on activities of daily living (p=0.61), as measured by the Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL). Neither group was significantly changed from baseline. The dimebon-treated group showed a 1.6 point improvement on behavior compared to placebo (p=0.17), as measured by the Neuropsychiatric Inventory (NPI). Compared to baseline, each group was improved, but this change was only significant for the dimebon group. On the Mini Mental State Examination (MMSE), another measure of cognition, both groups improved significantly over baseline (dimebon 0.7; placebo 1.2). The difference favoring placebo was not significant (p=0.10). Results for the dimebon 5 mg dose were similar to dimebon 20 mg and placebo, although they were numerically lower. Dimebon, 20 mg orally three-times daily, was well tolerated in the study. The number of patients with at least one adverse event was similar in the dimebon 20 mg and placebo groups (72.0% vs. 74.2%, respectively). The most frequently reported adverse events (>5%) in patients in the 20 mg dimebon group occurring more commonly than in the placebo group included somnolence (11.0% vs. 10.1%), dry mouth (8.5% vs. 6.6%), headache (9.5% vs. 5.6%), dizziness (7.5% vs. 5.1%), constipation (5.5% vs. 3.5%), cough (7.5% vs. 3.5%) and depression (6.0% vs. 3.5%). Similar rates of adverse events were observed for the 5 mg TID group. No clinically significant findings were noted in assessment of vital signs, clinical laboratories or on electrocardiography (ECG)."
Read the full release
===
Alzheimer’s Association statement on negative Phase III trial results for latrepirdine (Dimebon)
03 March 2010
Read the statement
===
From ABC News:
Pfizer Alzheimer's Drug Dimebon Fails in Study
Late Stage Trials Show No Effect But Drug May Still Have a Future
By COURTNEY HUTCHISON
ABC News Medical Unit
March 03, 2010
"Dimebon, a once-promising new Alzheimer's drug from Pfizer Inc., may be no more effective than a placebo at treating the disease, according to late-stage clinical data released by the company Wednesday."
Read the full article
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 14; Authors: Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans...
- Alzheimer Disease: Dimebon Results, Part Ii
From The New York Times: Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing...
- Neuropsychology Abstract Of The Day: Agitation In Alzheimer's Disease (ad)
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation...
- Abstract Of The Day: Alzheimer Disease Drug Treatments
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD005593. BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients...
- Modafinil For Fatigue In Multiple Sclerosis
B. Stankoff, MD, PhD, E. Waubant, MD, PhD, C. Confavreux, MD, G. Edan, MD, M. Debouverie, MD, L. Rumbach, MD, T. Moreau, MD, PhD, J. Pelletier, MD, PhD, C. Lubetzki, MD, PhD, M. Clanet, MD, PhD and French Modafinil Study Group. Modafinil for fatigue in...